Zynerba Pharmaceuticals Stock Book Value Per Share
| ZYNEDelisted Stock | USD 0.36 0.01 2.70% |
Zynerba Pharmaceuticals fundamentals help investors to digest information that contributes to Zynerba Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Zynerba Stock. The fundamental analysis module provides a way to measure Zynerba Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Zynerba Pharmaceuticals stock.
Zynerba |
Zynerba Pharmaceuticals Company Book Value Per Share Analysis
Zynerba Pharmaceuticals' Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
More About Book Value Per Share | All Equity Analysis
Book Value per Share | = | Common EquityAverage Shares |
Current Zynerba Pharmaceuticals Book Value Per Share | 0.57 X |
Most of Zynerba Pharmaceuticals' fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Zynerba Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
CompetitionIn accordance with the recently published financial statements, the book value per share of Zynerba Pharmaceuticals is about 0.575 times. This is 133.82% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The book value per share for all United States stocks is 99.97% higher than that of the company.
Zynerba Book Value Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Zynerba Pharmaceuticals' direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Zynerba Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Zynerba Pharmaceuticals by comparing valuation metrics of similar companies.Zynerba Pharmaceuticals is currently under evaluation in book value per share category among its peers.
Zynerba Fundamentals
| Return On Equity | -0.87 | |||
| Return On Asset | -0.45 | |||
| Current Valuation | 28.33 M | |||
| Shares Outstanding | 53.94 M | |||
| Shares Owned By Insiders | 6.07 % | |||
| Shares Owned By Institutions | 12.12 % | |||
| Number Of Shares Shorted | 419.98 K | |||
| Price To Earning | (3.84) X | |||
| Price To Book | 0.54 X | |||
| Price To Sales | 1,153 X | |||
| EBITDA | (34.62 M) | |||
| Net Income | (35.04 M) | |||
| Cash And Equivalents | 62.49 M | |||
| Cash Per Share | 1.44 X | |||
| Total Debt | 334.43 K | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 6.89 X | |||
| Book Value Per Share | 0.57 X | |||
| Cash Flow From Operations | (23.03 M) | |||
| Short Ratio | 0.26 X | |||
| Earnings Per Share | (0.80) X | |||
| Target Price | 1.25 | |||
| Number Of Employees | 25 | |||
| Beta | 1.19 | |||
| Market Capitalization | 70.12 M | |||
| Total Asset | 55.52 M | |||
| Retained Earnings | (274.52 M) | |||
| Working Capital | 45.6 M | |||
| Current Asset | 43.42 M | |||
| Current Liabilities | 3.94 M | |||
| Net Asset | 55.52 M |
About Zynerba Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Zynerba Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Zynerba Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Zynerba Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Current Watchlist to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Other Consideration for investing in Zynerba Stock
If you are still planning to invest in Zynerba Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Zynerba Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |